Canadian International Pharma Corp. Provides Company Update

West Vancouver, British Columbia, September 15, 2016 – Canadian International Pharma Corp. (the “Company” or “CIPC”) – CIPC is pleased to provide an update on the Company’s ongoing efforts to grow its business and to generate shareholder value.

PharmaCert Program

One of CIPC’s major focusses is its PharmaCert Program. PharmaCert is a Canadian certification program for finished dosage forms of nutraceutical and pharmaceutical medications manufactured around the world. To date, CIPC has received two expressions of interest from major international manufacturers through its online registration system. The Company is working closely with these two manufacturers in an effort to enter into contracts to provide the PharmaCert Program for their multiple medications. For more information about the PharmaCert program, visit the company’s dedicated website at

Cross Licensing

CIPC cross licenses generic and nutraceutical medications manufactured by international companies. The company can provide services to register these medications in North American markets. Once registered, CIPC offers sales and marketing programs to promote these medications in Canadian and US markets.

Business Development Agents

As part of its plan to develop and generate generic and nutraceutical sales for the Company, CIPC is actively engaging independent sales agents in strategic regions worldwide. To date, the Company has engaged 5 Business Development Agents covering the Middle East, Europe, Dubai, Iran, Egypt and India, and will continue to engage qualified agents that can provide resources and quality business contacts to develop sales in new territories.

Conference and Trade Show Presence

In an effort to develop business and to build stronger relationships with international manufacturing and distribution companies, CIPC plans to attend several conferences and trade shows in the coming year. Initially, the Company’s management and its Business Development Agents are planning to attend two upcoming shows, including:

Fierce Biotech Drug Development Conference – September 19-21, 2016 in Boston, MA

Leading pharmaceutical and biotech professionals will convene to discuss and evaluate the latest challenges, trends and innovations in drug discovery, research and development.

CPhI Worldwide – October 4-6, 2016 in Barcelona, Spain

The exhibition showcases the whole spectrum of pharmaceutical manufacturing and ingredients sourcing, offering products and services that cover the entire supply chain. Join Dr. Mack Payravi at meeting space in Hall 5 at 5G46, where he has 17 introductory meetings booked with European, Indian and Eastern European pharma manufacturers confirmed to date.

About Canadian International Pharma Corp.

Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. CIPC has recently launched its PharmaCert Program. PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at

“Douglas L. Mason”
Douglas L. Mason, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.


This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.